🚀 VC round data is live in beta, check it out!
Hybio Pharmaceutical Valuation Multiples
Discover revenue and EBITDA valuation multiples for Hybio Pharmaceutical and similar public comparables like Piramal Pharma, Jiuzhou Pharmaceutical, PharmaResearch, ST Pharm and more.
Hybio Pharmaceutical Overview
About Hybio Pharmaceutical
Hybio Pharmaceutical Co Ltd is engaged in manufacturing and sale of peptide products. The company's peptide finished dosage products include digestive system agents, immune modulators, hormone and endocrine modulators, antiviral agents, and hemostatic products. It also provides peptide CRO and CMO services, as well as API products.
Founded
2003
HQ
Employees
N/A
Website
Financials (FY)
EV
$3B
Hybio Pharmaceutical Financials
Hybio Pharmaceutical reported last fiscal year revenue of $86M and EBITDA of $13M.
In the same fiscal year, Hybio Pharmaceutical generated $49M in gross profit, $13M in EBITDA, and had net loss of ($25M).
Hybio Pharmaceutical P&L
In the most recent fiscal year, Hybio Pharmaceutical reported revenue of $86M and EBITDA of $13M.
Hybio Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $86M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $49M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 57% | XXX | XXX | XXX |
| EBITDA | — | XXX | $13M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 16% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 4% | XXX | XXX | XXX |
| Net Profit | — | XXX | ($25M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (29%) | XXX | XXX | XXX |
| Net Debt | — | — | $204M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Hybio Pharmaceutical Stock Performance
Hybio Pharmaceutical has current market cap of $2B, and enterprise value of $3B.
Market Cap Evolution
Hybio Pharmaceutical's stock price is $2.66.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $2B | 0.2% | XXX | XXX | XXX | $-0.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialHybio Pharmaceutical Valuation Multiples
Hybio Pharmaceutical trades at 30.4x EV/Revenue multiple, and 194.4x EV/EBITDA.
Hybio Pharmaceutical Financial Valuation Multiples
As of March 21, 2026, Hybio Pharmaceutical has market cap of $2B and EV of $3B.
Equity research analysts estimate Hybio Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Hybio Pharmaceutical has a P/E ratio of (93.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 30.4x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 194.4x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 858.7x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 53.3x | XXX | XXX | XXX |
| P/E | — | XXX | (93.1x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 367.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Hybio Pharmaceutical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Hybio Pharmaceutical Margins & Growth Rates
Hybio Pharmaceutical's revenue in the last fiscal year grew by 37%.
Hybio Pharmaceutical Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 37% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 16% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (139%) | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 17% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 15% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 54% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Hybio Pharmaceutical Public Comps
See public comps and valuation multiples for other Contract Research & Manufacturing comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Piramal Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Jiuzhou Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| PharmaResearch | XXX | XXX | XXX | XXX | XXX | XXX |
| ST Pharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Sai Life Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hybio Pharmaceutical M&A Activity
Hybio Pharmaceutical acquired XXX companies to date.
Last acquisition by Hybio Pharmaceutical was on XXXXXXXX, XXXXX. Hybio Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Hybio Pharmaceutical
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialHybio Pharmaceutical Investment Activity
Hybio Pharmaceutical invested in XXX companies to date.
Hybio Pharmaceutical made its latest investment on XXXXXXXX, XXXXX. Hybio Pharmaceutical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Hybio Pharmaceutical
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Hybio Pharmaceutical
| When was Hybio Pharmaceutical founded? | Hybio Pharmaceutical was founded in 2003. |
| Where is Hybio Pharmaceutical headquartered? | Hybio Pharmaceutical is headquartered in China. |
| Who is the CEO of Hybio Pharmaceutical? | Hybio Pharmaceutical's CEO is Yu Pinxiang. |
| Is Hybio Pharmaceutical publicly listed? | Yes, Hybio Pharmaceutical is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Hybio Pharmaceutical? | Hybio Pharmaceutical trades under 300199 ticker. |
| When did Hybio Pharmaceutical go public? | Hybio Pharmaceutical went public in 2011. |
| Who are competitors of Hybio Pharmaceutical? | Hybio Pharmaceutical main competitors are Piramal Pharma, Jiuzhou Pharmaceutical, PharmaResearch, ST Pharm. |
| What is the current market cap of Hybio Pharmaceutical? | Hybio Pharmaceutical's current market cap is $2B. |
| What is the current revenue of Hybio Pharmaceutical? | Hybio Pharmaceutical's last fiscal year revenue is $86M. |
| What is the current EV/Revenue multiple of Hybio Pharmaceutical? | Current revenue multiple of Hybio Pharmaceutical is 30.4x. |
| Is Hybio Pharmaceutical profitable? | No, Hybio Pharmaceutical is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.